Genomic and drug discovery company OutSee has closed a £2.5 million ($3.4 million) seed funding round and partnered with contract research organisation o2h discovery to develop a lead drug target candidate. 

The partnership aims to launch a collaborative drug discovery programme for OutSee’s lead target candidate, identified through the company’s genomic target discovery and precision medicine platform, Nomaly. 

Finance raised in the seed funding round will enable OutSee to advance therapeutic targets through experimental validation and generate a strong internal pipeline of assets. The funding will also support ongoing R&D of the Nomaly platform, which uses a ‘genomics first’ approach to target identification, to enhance the core technology and transition from validation to active value generation. 

“Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery,” said Dr Julian Gough, CEO and Founder of OutSee. 

“The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team.” 

“o2h discovery prioritises insight-driven science and OutSee’s pioneering approach to target identification facilitates just that, holding the potential to unlock a new wave of therapeutic targets,” added Prashant Shah, Co-Founder of o2h Group. 

“The technology is disruptive and enables datasets to be analysed in a completely new way, even those that have already been combed using traditional methods. We look forward to working together and leveraging our respective expertise to drive this programme forward.” 

Bruno Quinney, Content Team, DDW